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Autosomal dominant parkinsonism has been attributed to pathogenic amino acid substitutions in leucine-rich repeat
kinase 2 (LRRK2). By sequencing multiplex families consistent with a PARK8 assignment, we identified a novel
heterozygous LRRK2 mutation. A referral sample of 248 affected probands from families with autosomal dominant
parkinsonism was subsequently assessed; 7 (2.8%) were found to carry a heterozygous LRRK2 6055GrA transition
(G2019S). These seven patients originate from the United States, Norway, Ireland, and Poland. In samples of
patients with idiopathic Parkinson disease (PD) from the same populations, further screening identified six more
patients with LRRK2 G2019S; no mutations were found in matched control individuals. Subsequently, 42 family
members of the 13 probands were examined; 22 have an LRRK2 G2019S substitution, 7 with a diagnosis of PD.
Of note, all patients share an ancestral haplotype indicative of a common founder, and, within families, LRRK2
G2019S segregates with disease (multipoint LOD score 2.41). Penetrance is age dependent, increasing from 17%
at age 50 years to 85% at age 70 years. In summary, our study demonstrates that LRRK2 G2019S accounts for
parkinsonism in several families within Europe and North America. Our work highlights the fact that a proportion
of clinically typical, late-onset PD cases have a genetic basis.
Parkinsonism is a clinical syndrome characterized by
bradykinesia, resting tremor, muscle rigidity, and pos-
tural instability (Gelb et al. 1999). Parkinson disease (PD
[(MIM 168600]) is the second most frequent neurode-
generative disorder, after Alzheimer disease; it affects11%
of the population aged 155 years and is the most com-
mon cause of parkinsonism (de Rijk et al. 1995). Neu-
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ropathological findings in PD are loss of pigmented neu-
rons in the brain stem—substantia nigra and locus coe-
ruleus—with intracellular Lewy body inclusions found
within surviving neurons (Forno 1996).
Although PD is considered a sporadic disease, various
hereditary forms of parkinsonism have been recognized
(Vila and Przedborski 2004). A major breakthrough in
recent years has been the mapping and cloning of a num-
ber of genes causing monogenic forms of parkinsonism.
The role of genetics in sporadic late-onset PD has, how-
ever, remained controversial due, in part, to the different
associated pathologies and the variable but overlapping
spectrum of clinical signs and symptoms seen in mono-
genic familial forms of parkinsonism.
Genomic multiplication and missense mutations in the
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Table 1
Novel Chromosome 12 STR Markers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
a-synuclein gene were initially identified in a small num-
ber of families with autosomal dominant parkinsonism
(PARK1 [MIM 168601] and PARK4 [MIM 605543])
(Polymeropoulos et al. 1997; Kruger et al. 1998; Sin-
gleton et al. 2003; Chartier-Harlin et al. 2004; Farrer et
al. 2004; Zarranz et al. 2004). Patients present with
levodopa-responsive parkinsonism, although early-onset
dementia is frequent (Spira et al. 2001). a-Synuclein an-
tibodies robustly stain Lewy bodies and Lewy neurites
in familial and sporadic PD (Spillantini et al. 1997), and
common genetic variability in the a-synuclein promoter
has been implicated in sporadic PD (Pals et al. 2004).
Autosomal recessive mutations in three genes—parkin,
DJ-1, and PINK1—have been linked with early-onset
(i.e., subjects aged !45 years at onset) parkinsonism
(PARK2 [MIM 600116 and MIM 602544], PARK6
[MIM 605909], and PARK7 [MIM 606324]) (Kitada et
al. 1998; Bonifati et al. 2003; Valente et al. 2004a). A
large number of pathogenic mutations and rearrange-
ments have been identified in the parkin gene (reviewed
by Mata et al. [2004]). Mutations in the DJ-1 and PINK1
genes seem to be more rare (Abou-Sleiman et al. 2003;
Valente et al. 2004b).
Our group recently identified pathogenic mutations
in a novel gene, the leucine-rich repeat kinase 2 gene
(LRRK2), in six families with autosomal dominant par-
kinsonism linked to the PARK8 locus (MIM 607060)
(Zimprich et al. 2004a). Paisan-Ruiz and colleagues
(2004) independently confirmed these findings in British
and Basque families. The PARK8 locus was originally
mapped in a large Japanese family, the Sagamihara fami-
ly, presenting with autosomal dominant parkinsonism
(Funayama et al. 2002). Across PARK8-linked families,
the age at onset of symptoms is late (aged 150 years),
albeit variable. Brain autopsy findings in four members
of the Sagamihara family showed pure nigral neuronal
degeneration without coexisting pathology (Funayama
et al. 2002). In contrast, nigral neuronal loss, tauopathy,
and Lewy body synucleinopathy have been described
elsewhere for families A and D (Wszolek et al. 2004;
Zimprich et al. 2004a).
Here, we describe a novel LRRK2 mutation in 13 fami-
lies from diverse North American and European origins.
Segregation analysis provided evidence of pathogenicity
and an estimate of age-associated penetrance, whereas
haplotype analysis suggested that the mutation origi-
nates from a common and ancient founder.
Patients and control individuals in this study were
examined by neurologists specialized in movement dis-
orders. A full history, including family history and neu-
rological examination, was completed for each patient.
A clinical diagnosis of PD required the presence of at
least two of three cardinal signs (resting tremor, brady-
kinesia, and rigidity), improvement through adequate
dopaminergic therapy, and the absence of atypical fea-
tures or other causes of parkinsonism. Families with two
or more members affected by PD in at least two con-
secutive generations were considered to be consistent
with an autosomal dominant pattern of inheritance. The
institutional review boards of all participating institu-
tions approved our clinicogenetic protocols, and in-
formed consent was obtained from all patients and con-
trol subjects.
Blood samples were taken and genomic DNA was
extracted using standard techniques. Six small families
(194, 281, 3081, 3082, 3083, and 3211) were identified
elsewhere with positive LOD scores (range 0.29–0.38)
for microsatellite markers within the PARK8 locus (Zimp-
rich et al. 2004b). For each of these probands, all 51
exons of the LRRK2 gene were amplified by PCR and
were sequenced. Electrophoresis was performed under
standard conditions on an ABI 3730 automated se-
quencer, and data were analyzed with SeqScape software
version 2.1.1 (Applied Biosystems) and were compared
with the published sequence of LRRK2 (GenBank ac-
cession number AY792511). Primers are available on
request.
On identification of a novel, heterozygous LRRK2
6055GrA transition (G2019S) in the proband and af-
fected sibling of family 3211, we designed a probe em-
ploying TaqMan chemistry on ABI 7900 (Applied Bio-
systems) to screen for this specific mutation. We ex-
amined another 242 affected probands with familial par-
kinsonism that was consistent with autosomal dominant
transmission of disease. These probands and their fami-
lies were referred from many regions of North Ameri-
ca, Asia, and Europe. Positive samples originated from
centers in the United States, Norway, Ireland, and Po-
land. Hence, we subsequently assessed whether LRRK2
6055GrA (G2019S) was common in appropriate popu-
lation samples. We screened 435 Norwegian, 271 Irish,
and 100 Polish patients with idiopathic PD and 1,200
American, 550 Norwegian, 330 Irish, and 180 Polish
control subjects (2,260 control individuals in total). All
mutations discovered were confirmed by direct sequenc-
ing. Finally, all participating family members of LRRK2
G2019S–substitution carriers (affected and unaffected)
were screened for the mutation.
In available family members, 17 microsatellite mark-
ers and four SNPs were genotyped for linkage analy-
ses and to determine whether a single haplotype was
associated with the LRRK2 mutation. Microsatellite
markers were chosen to span the PARK8 region, in-
cluding D12S87, D12S1648, D12S2080, D12S2194,
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Table 2
Allele Frequencies of PARK8 Markers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 1 Chromosome 12q12 markers on the disease haplotype (PARK8). Genotypes for mutation carriers from 13 families with LRRK2
G2019S are shown; those shared are highlighted in gray. For families whose phase could not be determined with certainty, both alleles are
shown.
D12S1048, D12S1301, and D12S1701. LRRK2 is lo-
cated between D12S2194 and D12S1048. We also de-
veloped 10 novel microsatellite markers in this region
(table 1) by searching for repeat polymorphisms by use
of the RepeatMasker software (RepeatMasker Web site)
with in silico BAC sequences covering the PARK8 locus
(University of California–Santa Cruz Genome Bioinfor-
matics). (The physical position of markers is from the
National Center for Biotechnology Information [NCBI]
build 34.) One primer of each pair was labeled with a
fluorescent tag. PCR reactions were performed under
standard conditions, and PCR products were run on an
ABI 3100 genetic analyzer. Results were analyzed using
Genescan 3.7 and Genotyper 3.7 software (Applied Bio-
systems). The four exonic LRRK2 SNPs included were
rs7966550, rs1427263, rs11176013, and rs11564148.
Marker-allele frequencies were estimated by genotyping
unrelated individuals from North America (table 2).
Multipoint LOD scores for all families were calculated
under the assumption of an autosomal dominant model
by use of GENEHUNTER-PLUS (Kong and Cox 1997).
The frequency of the deleterious allele was set at 0.0001;
marker-allele frequencies were determined empirically.
The map positions for each marker were taken from
Rutgers combined linkage physical map, version 1.0
(MAP-O-MAT Web site). For tightly linked loci with no
observed recombinants, intermarker genetic distances
were assigned as 0.01 cM. PARK8 haplotypes were es-
tablished for families with known phase; for those af-
fected individuals or families for whom chromosomal
phase could not be determined, both alleles are given
(fig. 1). Haplotype frequencies in the general population
were estimated from unrelated individuals by use of an
estimation-maximization algorithm (Zaykin et al. 2002).
Age-dependent penetrance was estimated as the prob-
ability of a gene carrier becoming affected, at a given
age, within the 13 families. The number of affected mu-
tation carriers within each 5-year age group was divided
by the total number of carriers (both affected and un-
affected) within that group. For some affected family
members, no DNA was available, and only historical data
on the disease course was obtained. Those individuals
were excluded from penetrance calculations.
We identified a heterozygous 6055GrA mutation in
7 (2.8%) of 248 probands from families presenting with
autosomal dominant parkinsonism. Subsequently, six ad-
ditional patients carrying the same mutation were iden-
tified through population-based screening in samples of
European descent. In total, we identified 13 families: 7
originate from Norway, 3 from the United States, 2 from
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Figure 2 Pedigrees of families with LRRK2 G2019S. Blackened symbols denote family members affected with parkinsonism. An asterisk
(*) denotes a genotyped individual, with “m” for mutation carriers and “wt” for wild-type LRRK2. To protect confidentiality, the genotypes
and sexes of some unaffected individuals are not shown, and some family members for whom no information was available have been removed
from the pedigrees.
Ireland, and 1 from Poland. Of the U.S. families, one
was reported to be of Russian/Romanian ancestry (fami-
ly 1120), a second claimed to be of Italian descent (fami-
ly 1210), and the ethnic origin was unknown for a third
kindred (family 111). After genotyping 42 additional
family members, 22 were found to carry the mutation,
7 with a diagnosis of PD (table 3).
Three of the six original patients identified through
the population-based screening had no known family
history of PD. In the 10 remaining kindreds, the LRRK2
G2019S substitution segregates with disease, consistent
with autosomal dominant transmission with reduced, age-
associated penetrance. Simplified versions of the family
pedigrees are presented in figure 2. Of note, a recently
deceased member of family P-089 was affected but was
not an LRRK2 mutation carrier. He had akinetic rigid
parkinsonism unresponsive to levodopa. Although his
chromosome 12q12 haplotypes were consistent with
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Figure 3 Penetrance of LRRK2-associated disease, showing the
probability of becoming affected by parkinsonism, in LRRK2 G2019S
carriers, as a function of age.
Figure 4 LRRK2 with the novel G2019S substitution. A, Schematic drawing of LRRK2 with predicted protein domains. LRRp leucine-
rich repeat; Roc p Ras in complex proteins; CORp C-terminal domain of Roc; MAPKKKp mitogen-activated protein kinase kinase kinase;
WD40 p WD40 repeats. B, The human LRRK2 protein sequence in the region of the G2019S mutation, aligned with orthologs from rat
(GenBank accession number XP_235581), mouse (GenBank accession number AAH34074), frog (GenBank accession number AAH76853), and
puffer fish (GenBank accession number CAG05593). The mutation is indicated by a blackened arrowhead. C, Chromatogram showing the
6055GrA transition (G2019S).
those of his offspring and siblings, he did not carry the
disease-associated PARK8 haplotype. Hence, for the
purposes of this study, he was considered a phenocopy
and was excluded from further analyses. We did not
identify the mutation in any of 2,260 control individuals.
Evidence for linkage to the PARK8 locus was found
across families, with a combined maximum multipoint
LOD (mLOD) score of 2.41, corresponding to a P value
of . Positive LOD scores were found in all44.3# 10
families in which more than one affected subject was
genotyped (table 3). Since only a defined chromosomal
region was investigated, rather than a genomewide search
being done, the mLOD score exceeds that required for
significance, (Lander and Kruglyak 1995).Pp .01
All affected members from the different families, ex-
cept the phenocopy in family P-089, share a chromo-
some 12q12 and LRRK2 haplotype (fig. 1). Phase can
be established for most markers in nine of the families;
LRRK2 6055GrA mutation carriers share alleles for
eight adjacent markers, including four exonic SNPs and
four microsatellites. For the remaining families, the num-
ber of available samples from relatives was not sufficient
to determine phase. However, the genotypes in these
cases are consistent with a common LRRK2 G2019S
allele. D12S2516 is located in intron 30, and D12S2518
is located in intron 45, whereas the two other shared
markers are positioned 3′ of the LRRK2 gene. SNP
rs7966550 is located in exon 22, and the remaining three
SNPs are in exon 34. With use of the physical position
of the shared and nonshared markers, the size of the
shared haplotype was determined to be between 145 kb
and 154 kb. The frequency of this haplotype is estimated
to be 6.0% in the U.S. population (not considering the
frequency of the LRRK2 6055GrA mutation).
Age at onset of clinical symptoms was variable, even
within the same family. Family 1120 had both the ear-
liest and latest age at onset for a patient. The youngest
affected patient had onset at age 39 years, whereas the
oldest carrier presented with initial symptoms at age 78
years. Where recorded, most LRRK2 G2019S carriers
have late-onset disease (aged 150 years at onset). The
mean age at onset for affected mutation carriers (np
) was 56.8 years (range 39–78 years). Unaffected car-19
riers ( ) have a mean age of 54.6 years (range 26–np 15
74 years). The penetrance of the mutation was found to
be highly age dependent, increasing from 17% at age
50 years to 85% at age 70 years (fig. 3).
We have identified a novel 6055GrA (G2019S)
LRRK2 mutation in 13 white kindreds originating from
several European and North American populations. In
10 families, the mutation segregates with autosomal
dominant parkinsonism; three probands had no family
678 Am. J. Hum. Genet. 76:672–680, 2005
Figure 5 Aligned amino acid sequences of the activation segment
of different human kinases.
history of PD. Positive mLOD scores were obtained in
multiplex families and, combined, provide significant
support for the PARK8 locus. The LRRK2 G2019S sub-
stitution was absent in a large number of control indi-
viduals of similar ethnicity. The physical size of the
shared haplotype is small, between 145 kb and 154 kb.
LRRK2 is located close to the centromere on chromo-
some 12, and there is generally a dearth of recombina-
tion at centromeres. LRRK2 spans several haplotype
blocks, but local patterns of linkage disequilibrium are
not available for the specific populations we have studied
(International HapMap Project). The mutant allele is
geographically widespread across European and Ameri-
can populations and is therefore likely to be ancient.
The number of families linked to LRRK2 in this and
previous studies now explains a proportion of geneti-
cally defined autosomal dominant parkinsonism greater
than that explained by other genes.
Age is the single most consistent risk factor for de-
velopment of PD and other neurodegenerative disorders
(Lang and Lozano 1998), and our data also indicate that
age is an important risk factor in LRRK2-associated
parkinsonism. The mean age at onset, 56.8 years, of
patients with the LRRK2 6055GrA mutation in this
study is comparable to that of patients in other families
linked to PARK8 (Funayama et al. 2002; Paisan-Ruiz et
al. 2004; Zimprich et al. 2004a). The majority of pa-
tients in all families present with late-onset disease that
is difficult to clinically distinguish from typical idio-
pathic PD. We found that the penetrance of of LRRK2
G2019S–associated disease was highly age dependent,
increasing in a close-to-linear fashion from 17% at age
50 years to 85% at age 70 years. Interestingly, age at
onset was variable in this study, both within and between
different families, which suggests that other susceptibil-
ity factors, environmental or genetic, may influence the
phenotype.
Although our findings clearly indicate that LRRK2
mutations account for a proportion of familial late-onset
parkinsonism, historically, cross-sectional twin studies
have not supported a genetic etiology for late-onset PD
(Tanner et al. 1999; Wirdefeldt et al. 2004). The age-
associated penetrance of LRRK2 mutations provides
some explanation, since even large and well-designed
twin studies are underpowered to detect incompletely
penetrant mutations (Simon et al. 2002). LRRK2 mu-
tations were also found in patients with apparently spo-
radic PD; three of the patients in the present study did
not have any known affected first- or second-degree rela-
tives. However, a caveat for the study of age-dependent
penetrance is that carriers may die of other diseases be-
fore manifesting or being diagnosed with PD. Thus, it
seems difficult to separate sporadic and familial PD and
to hypothesize environmental causes as more important
in one group and genetic causes as more prominent in
the other. In light of these results, a family history of
parkinsonism, previously considered an exclusion cri-
terion for a diagnosis of PD, must be reconsidered
(Hughes et al. 1992).
LRRK2 is a member of the recently defined ROCO
protein family (Bosgraaf and Van Haastert 2003). In
human, mouse, and rat, members of the ROCO protein
family have five conserved domains (fig. 4). The LRRK2
kinase domain belongs to the MAPKKK subfamily of
kinases. The active sites of all kinases are located in a
cleft between an N-terminal and a C-terminal lobe, typi-
cally covered by an “activation segment,” in an inactive
conformation. The activation segment must undergo
crucial structural changes to allow access to peptide sub-
strates and to orient key catalytic amino acids (Huse and
Kuriyan 2002). In different kinases, the activation seg-
ment starts and ends with the conserved residues asp-
phe-gly (DFG) and ala-pro-glu (APE), respectively (No-
len et al. 2004). The LRRK2 G2019S substitution
changes the highly conserved glycine (G) at the start of
this segment (fig. 5). In a German family we described
elsewhere, an I2020T mutation is located in an adjacent
codon (Zimprich et al. 2004a). In other kinases, onco-
genic mutations in residues within the activation seg-
ment of the kinase domain have an activating effect
(Davies et al. 2002). Thus, we postulate that LRRK2
G2019S and I2020T mutations may have an activating
effect on the kinase activity of LRRK2. A mutation caus-
ing “gain of function” of the resulting protein would
also be compatible with the dominant mode of disease
transmission observed in the presented families.
The identification of LRRK2 mutations as a cause of
parkinsonism in a large number of families from differ-
ent populations heralds an exciting time in the field of
neurogenetics. The elucidation of the functional effects
of this gene and of the G2019S substitution will further
our understanding of pathways that play a pivotal role
in PD.
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